Press

Osmind Closes $15 Million Series A Round to Help Clinicians and Researchers Bring Innovative Mental Health Treatments to More Patients

Jul 2 • 5 min read

Quick Take: The funding comes from a number of angel investors with experience in the industry. Funding will support expansion of Osmind’s neuropsychiatry software platform and team growth Osmind, a healthcare technology company building the first digital infrastructure for neuropsychiatry, closed $15 million in Series A funding to further develop and expand its electronic health…

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Jun 29 • 3 min read

Quick Take: Tryp Therapeutics has partnered with Alcami Corporation to develop oral formulations for Tryp’s psilocybin active pharmaceutical ingredient. Tryp Therapeutics (CSE:TRYP), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO), to support the…

COMPASS Pathways completes COMP360 psilocybin therapy administration

Jun 28 • 3 min read

Quick Take: COMPASS Pathways has completed their flagship COMP360 psilocybin therapy administration for 216 patients. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has completed psilocybin administration to the target 216 patients in its phase IIb clinical trial…

SpeakEasy Announces Proposed Strategic Acquisition of Karolos Research Inc.

Jun 25 • 4 min read

Quick Take: SpeakEasy has entered into an agreement to acquire British Colombia psychedelic company Karolos. SpeakEasy Cannabis Club Ltd. (CSE: EASY), a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act, is pleased to announce that it has entered into a share purchase agreement dated June 24, 2021 among the Company, Karolos Research…

Filament Health Corp. Announces Approval for Listing on the NEO Exchange

Jun 24 • 3 min read

Quick Take: Filament Health, a psychedelic drug discovery company, has announced the approval for their listing on the NEO exchange Filament Health Corp., (NEO: FH) an exclusively-natural psychedelic drug discovery and extraction technology company, is pleased to announce it has received final approval to list its common shares on the Neo Exchange Inc. (the “NEO”)…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435